|
ABOUT COMPANY
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
|
EARNINGS
Gross Profit (TTM): -620801
Market Capitalization: 25079500
Operating Margin (TTM): -13.43
PE Ratio: None
PEG Ratio: 0
Profit Margin: 0
Revenue Per Share (TTM): 0.086
Revenue (TTM): 472160
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: -0.927
Trailing PE: -
|
DIVIDENDS
Diluted EPS (TTM): -1.129
Dividend Date: 2020-09-25
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: -2643480
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|